ABT Q3 FY2026 earnings call — BigGo Finance
Abbott Laboratories (ABT) reported Q3 2026 sales growth of 7% YoY, with adjusted EPS of $1.42, meeting expectations. Growth was driven by diagnostics, medical devices, and nutrition. The company plans to spin off its nutrition business, expected to complete by the end of 2027, with the new entity having $8.5B in annual sales. Abbott revised its full-year 2026 sales growth guidance to approximately 6%, with Q4 growth just above 8%.
How this was made
The 30-second read
Why it matters
The earnings beat and spin‑off announcement together create a fresh catalyst for price movement.
Market read
The combination of solid earnings and a strategic spin‑off provides actionable insight for traders focusing on health‑care equities.
What to watch
Exact timing of the spin‑off and regulatory approvals may delay expected benefits.
Background
Abbott's Q3 earnings call provided detailed segment performance and introduced a major corporate restructuring.
Ticker impact
Abbott reported Q3 FY2026 results with 7% sales growth, adjusted EPS $1.42 and announced a tax‑free spin‑off of its nutrition business.
likely modest upside as investors price in higher margins and the spin‑off premium.
Strong top‑line, margin expansion, and a clear value‑creation plan from the nutrition spin‑off provide a clear catalyst.
Market effects
Nutrition and health‑care sectors may see re‑rating as Abbott separates a pure‑play nutrition company.
U.S. healthcare stocks could benefit from the spin‑off narrative.
Limited to investors tracking large‑cap US health‑care and spin‑off opportunities.
Counterpoint
Spin‑off execution risk and potential dilution could weigh on the stock if integration challenges arise.
Key entities
- companyAbbott Laboratories
US‑listed health‑care conglomerate reporting Q3 FY2026 results.
- executiveDaniel Salvadori
Group President of Established Pharmaceuticals and Nutrition Products, appointed CEO of the future nutrition spin‑off.




